Narrowing Part D Protected Classes Won’t Be Proposed Again – Tavenner
This article was originally published in The Pink Sheet Daily
CMS Administrator Tavenner provides public assurances that the agency will not reintroduce a proposal to remove antidepressants, antipsychotics and immunosuppressants from protected status in the Medicare Part D program.
You may also be interested in...
Concerns about reducing patient protections will resonate with the Biden Administration and the Medicare Part D protected classes aren’t major cost drivers anyway, Avalere’s Mendelson says.
Decision in final rule marks a setback in the Trump Administration’s game plan for lowering drug prices. But CMS proceeds with codifying previous guidance allowing step therapy for Part B drugs in Medicare Advantage.
Congressional objections to proposal join opposition by patient and physician groups.